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Background: Chinese medicine is commonly used and covered by health insurance to treat symptoms of uterine
fibroids in Taiwan. This retrospective cohort study compared the consumption of conventional western medicine
and medical cost between Chinese medicine (CM) users and nonusers among patients with uterine fibroids.
Methods: We extracted 44,122 patients diagnosed with uterine fibrosis between 1996 and 2010 from the National
Health Insurance reimbursement database, which is a population-based database released by a government-run
health insurance system. Multivariate linear regression models were used to find association between using Chinese
medicine and the consumption of conventional medicine, and between using Chinese medicine and medical cost.
Results: The total fibroid-related conventional western medicine consumed by CM users was less than that by nonusers
(β = -10.49, P < 0.0001). Three categories of conventional medicines, including antianemics (-3.50 days/year/patient,
P < 0.0001), hemostatics (- 1.89 days/year/patient, P < 0.0001), and hormone-related agents (-3.13 days/year/patient,
P < 0.0001), were used less in patients who were CM users. Moreover, although using CM increased 16.9 USD per
patient in CM users annually (P < 0.0001), the total annual medical cost for treating fibroid was 5610 USD less in
CM users than in nonusers (P < 0.0001).
Conclusions: Our results suggested that CM reduced the consumption of conventional medicine, and might be a
potential therapeutic substitute for conventional western medicines to treat uterine fibroids with low cost.
Keywords: Uterine fibroid, Chinese medicine, Conventional western medicine, Iron-deficiency anemia,
Hypermenorrhea, DysmenorrheaBackground
Uterine fibroids are the most common benign uterine
tumors, which happens in 60% of reproductive aged
women [1]. The majority of fibroids are asymptomatic,
while in 20% of patients it causes symptoms such as
hypermenorrhea, dysmenorrhea, iron-deficiency anemia,
and infertility [2]. In symptomatic patients, the first-line* Correspondence: shanyusu@yahoo.com.tw
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unless otherwise stated.treatment is surgery. However, since surgery often cause
complications, conservative medical treatment to control
symptoms related to fibroids are frequently adopted by
patients and gynecologists [3]. Available indicated med-
ical treatments include antianemics (blood derivatives
and iron preparations) to treat iron-deficient anemia,
hemostatics (coagulants and anti-fibrinolytic agents) to
reduce bleedings of hypermenorrhea, and non-steroid
anti-inflammatory drugs (NSAIDs) to relief pain. As no
currently validated medical treatment is capable of mak-
ing fibroid disappear, there are no reason to consider
medical treatment in case of asymptomatic fibroids [4].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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includes cost of surgery, hospital admission, outpatient
visit, and medication. The annual cost of uterine fibroids
is up to 4.1-9.4 billion US dollars (USD) in the United
States [5,6], including 3.27 to 5.10 billion USD in non-
surgical management and 829 million to 4.3 billion USD
annually in surgical management [5]. If the indirect cost,
including lost work-hour costs and obstetric outcomes
cost, is taken into account, uterine fibroids are estimated
to cost the United States 5.9 - 34.4 billion USD annually
[5]. In European countries, the number of hospital ad-
missions involving treatment for uterine fibroids ranges
from 0.71 to 1.53 per 1000 women, and the estimated
direct cost related to uterine fibroids ranges from two to
five euros per woman [7].
Chinese medicine (CM) is an alternative and comple-
mentary medicine to treat gynecological diseases in
Asian countries [8-10]. Among fibroid patients, three
fourth of them have the experience of utilizing CM,
which are considered to be with fewer side effects, less
expensive [11,12], less subsequent surgery rate [13], and
higher life quality than conventional western medicine
[14]. Because of the high usage rate, the expense of CM
in Taiwan has been covered by the government-run
National Health Insurance (NHI) system since 1995
[15]. Despite of the above-mentioned advantages, it is
still unclear that whether use of CM decrease the con-
sumption of conventional western medicine, in the case
of that CM users usually have more symptoms than CM
nonusers [13], and are supposed to use more medical re-
sources. Moreover, as CM generates a new component
of medical cost, whether the use of CM decreases the
total medical cost also needed to be clarified.
In comparing fibroid patients who were CM users
with CM nonusers, we sought to determine: (1) if
the use of CM correlates with the consumption of
conventional western medicines that is specifically
for symptoms related to fibroids, and, (2) if the use




Patients with uterine fibroids were identified according
to the International Classification of Diseases, 9th Revi-
sion, Clinical Modification (ICD-9-CM) code 218 from
1996 to 2010 in the Longitudinal Health Insurance
Database 2000 (LHID2000). The LHID2000 was set up
by Taiwan’s National Health Research Institute and it
contains chronological information about one million
randomly selected individuals who were beneficiaries
from 1996 to 2000. This study was approved by the
Research Ethics Committee of the CMUH (CMU-REC-
101-012).Study designs
The date of the first diagnosis was used as the entry
date, and the endpoint date was December 31th 2010,
the date of death, withdrawal from the insurance pro-
gram, or underwent uterine surgery. The follow-up time
was defined as the period from the diagnosis date to the
endpoint date. CM users were defined as subjects who
had received a mean orally administered CM treatment
for more than fifteen days per year. The total fibroid -
related consumption of western medicines was estimated
by summarizing the number of days for which western
medicines have been prescribed with a ICD-9-CM code
of 218 from the diagnosis date to the endpoint date.
Medical costs included insurance claim for the NHI re-
imbursement for outpatients (OPD), inpatients (IPD),
emergency room (ER), and CM treatments that was
related to uterine fibroid.
The examined variables included socio-demographic
factors, including age (<20, 20 – 29, 30 -39, 40-49,
and > 50 years), income level (<520, 520 -639, 640 – 759,
and ≥ 759 USD, based on quartile), and occupation status
(white collar, blue collar, and others), and endometriosis-
related co-morbidities, including hypermenorrhea (ICD-
9-CM 626.2), iron-deficiency anemia (ICD-9-CM 280),
dysmenorrhea (ICD-9-CM 625.3), and infertility (ICD-
9-CM 628 and 628.3).
Statistical analysis
In terms of categorical and ordinal variables, CM users and
CM nonusers were compared using chi-square tests and
Wilcoxon rank sum test, respectively. Multivariate linear
regression models were performed to identify the inde-
pendent factors associated to the consumption of western
medicines, and to assess annual costs in OPD, IPD, ER, and
CM, as well as total annual medical cost. These adjusted
models were controlled for age, occupation, income, and
co-morbidities (hypermenorrhea, iron-deficiency anemia,
dysmenorrhea, and infertility). Continuous data are
expressed as mean ± SD and categorical data are expressed
as number and percentage. All statistical analyses were
performed using SAS software, version 9.1 (SAS Institute
Inc., Carey, NC), and the significance level was set at a
two-tailed P value of less than 0.05.
Results
Study subjects
A total of 44,122 women diagnosed with uterine fibrosis
between 1996 and 2010 were extracted from the LHID2000
database with a mean follow-up time of 4.6 years. Among
them, 11,412 patients were identified as CM users, and
32,710 patients were identified as CM nonusers. The mean
age of CM users (41.4 years) was younger than CM nonu-
sers (42.4 years) (Table 1). The proportions of patients
among CM users who were white collar, and registered
Table 1 Comparison of socio-demographic factors and co-morbidities between Chinese medicine (CM) users and nonu-
sers in patients with uterine fibroids
CM
Nonusers Users Total P-valuea
N = 32710 N = 11412 N = 44122
n % n % n %
Age, years < 0.0001
<20 202 0.6 47 0.4 249 0.5
20-29 2634 8.1 1030 9.0 3664 8.3
30-39 8998 27.5 3665 32.1 12663 28.7
40-49 15559 47.6 5167 45.3 20726 47.0
≥50 5317 16.5 1503 13.2 6820 15.5
Mean ± SD 42.4 ± 8.9 41.4 ± 8.5 42.2 ± 8.8
Income, US$ per month 0.1800
<520 8075 24.7 2725 23.9 10800 24.5
520 - 639 8173 25.0 2966 26.0 11139 25.3
640- 759 8556 26.2 2921 25.6 11477 26.0
≥760 7906 24.2 2800 24.5 10706 24.3
Mean ± SD 20098 ± 12630 20333 ± 12136 20158 ± 12505
Occupational status <0.0001
White collar 19243 58.8 6972 61.1 26215 59.4
Blue collar 9900 30.1 3312 29.0 13212 29.9
Others 3567 10.9 1128 9.9 4695 10.6
Area <0.0001
Northern Taiwan 16281 50.0 4820 42.2 21101 47.8
Central Taiwan 5758 17.6 2656 23.3 8414 19.1
Southern Taiwan 9265 28.3 3511 30.8 12776 29.0
Eastern Taiwan and offshore islands 1406 4.3 425 3.7 1831 4.15
Co-morbidity
Iron-deficiency anemia 5259 16.1 2213 19.4 7472 16.9 <0.0001
Hypermenorrhea 8388 25.6 3650 32.0 12038 27.3 <0.0001
Dysmenorrhea 7456 22.8 4246 37.2 11702 26.5 <0.0001
Infertility 2570 7.9 1358 11.9 3928 8.9 <0.0001
aChi-square test and Wilcoxon rank sum test.
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among CM nonusers. Moreover, the proportions of patients
who were co-morbid with iron-deficiency anemia, hyper-
menorrhea, dysmenorrhea, and infertility were all higher
among CM users than they were among CM nonusers.
Factors associated with the consumption of conventional
western medicine
The mean number of days of fibroid-related western
medicine taking was 14.6 ± 50.6 days per year. After
adjusting for socio-demographic factors (age, income,
occupation, and area), and co-morbid covariates (hyper-
menorrhea, iron-deficiency anemia, dysmenorrhea, and
infertility) in a multivariate linear regression model, CMusers consumed less western medicine than CM nonu-
sers (-10.5 days/year/patient, P < 0.0001). Patients who
aged higher than 40 years, who were blue collar, who
registered their insurance in Central Taiwan, and whose
income were less than 520 USD/month tended to
consume more conventional western medicine. Patients
whose diseases were co-morbid with hypermenorrhea,
iron-deficiency anemia (both P < 0.0001), and dysmenor-
rhea (P = 0.0202) also consumed more western medicine
than who were not co-morbid with these illnesses.
However, patients whose diseases were co-morbid with
infertility tended to consumed less western medicine
than whose diseases were not co-morbid with infertility
(P = 0.0295) (Table 2).
Table 2 Multivariate linear regression for number of days of fibroid-related treatment in patients with uterine fibroid
Days/yeara Estimate β VIFb T P
CM
Nonusers 17.2 ± 56.8 - - - -
Users 7.4 ± 24.3 -10.49 1.03 -19.03 <0.0001
Age, years
<20 3.5 ± 15.1 - - - -
20-29 6.1 ± 27.3 4.22 14.49 1.29 0.1971
30-39 11.0 ± 41.3 8.75 37.28 2.73 0.0063
40-49 18.4 ± 58.3 15.41 45.19 4.82 <0.0001
≥50 15.0 ± 50.6 13.07 24.33 4.03 <0.0001
Income, US$ per month
<520 14.7 ± 50.5 - - - -
520 - 639 13.9 ± 48.7 -1.22 1.57 -1.78 0.0745
640- 759 17.1 ± 56.2 -0.36 1.94 -0.48 0.6300
≥760 12.8 ± 45.9 -2.46 1.67 -3.44 0.0006
Occupational status
White collar 13.2 ± 47.3 - - - -
Blue collar 17.2 ± 56.4 1.70 1.48 2.70 0.007
Others 15.1 ± 50.9 1.18 1.14 1.43 0.1514
Area
Northern Taiwan 13.2 ± 47.7 - - - -
Central Taiwan 17.0 ± 54.2 3.57 1.16 5.48 <0.0001
Southern Taiwan 16.0 ± 53.4 2.25 1.20 3.92 <0.0001
Eastern Taiwan and offshore islands 12.4 ± 44.4 -2.37 1.07 -1.92 0.0543
Hypermenorrhea
No 13.1 ± 48.4 - - -
Yes 18.8 ± 55.8 3.99 1.08 7.21 <0.0001
Iron-deficiency anemia
No 12.3 ± 45.8 - - -
Yes 26.2 ± 68.4 12.8 1.04 19.83 <0.0001
Dysmenorrhea
No 14.8 ± 52.0 - - -
Yes 14.2 ± 46.3 1.32 1.13 2.32 0.0202
Infertility
No 15.2 ± 51.7 - - -
Yes 9.5 ± 36.4 -1.88 1.08 -2.18 0.0295
aR-square = 0.0277 and adjusted R-square = 0.0274 in a multivariate linear regression model that was adjusted for age, income, occupation, area, and iron-deficiency
anemia, infertility, excessive bleeding, and dysmenorrhea.
bVIF, variance inflation factor.
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analgesics, and hormone-related agents between CM users
and nonusers
Taking all the subjects as a whole, multivariate linear
regression revealed that CM users consumed less antia-
nemics (-3.50 days/year/patient, P < 0.0001), hemostatics
(- 1.89 days/year/patient, P < 0.0001), and hormone-relatedagents (-3.13 days/year/patient, P < 0.0001) than CM
nonusers (Table 3). Stratification analysis showed that
differences between CM users and nonusers in the
consumption of antianemics substantially enlarged in
patients with iron-deficiency anemia (-11.29 days/year/
patient, P < 0.0001), that of hemostatics enlarged in patients
with dysmenorrhea (-4.01 days/year/patient, P < 0.0001),
Table 3 Consumption of antianemics, hemostatics, and analgesics in patients co-morbid with iron-deficiency anemia,
hypermenorrhea, and dysmenorrhea
CM nonusers CM users Linear regression model
days/year days/year β (SE)a P-value
Total, Nb 32710 11412
Antianemicsc 7.7 ± 39.3 4.9 ± 23.4 -3.50 (0.38) < 0.0001
Hemostatics 4.1 ± 24.1 2.6 ± 12.2 -1.89 (0.24) < 0.0001
Analgesics 38.0 ± 62.5 38.0 ± 50.3 -0.42 (0.64) 0.5145
hormone-related agents 16.4 ± 57.3 13.9 ± 39.7 -3.13 (0.58) < 0.0001
Iron-deficient anemia, nb 5259 2213
Antianemics 30.9 ± 73.5 19.1 ± 43.4 -11.29 (1.68) < 0.0001
Hemostatics 8.3 ± 34.6 5.2 ± 19.3 -3.36 (0.79) < 0.0001
Analgesics 44.8 ± 70.2 42.8 ± 57.4 -2.24 (1.69) 0.1849
hormone-related agents 14.2 ± 40.6 14.0 ± 31.5 -1.20 (1.27) 0.34
Hypermenorrhea, n 8388 3650
Antianemics 13.2 ± 49.6 8.5 ± 28.8 -5.17 (0.85) < 0.0001
Hemostatics 7.9 ± 34.2 4.0 ± 13.5 -4.01 (0.59) < 0.0001
Analgesics 41.7 ± 63.3 38.9 ± 47.4 -3.51 (1.16) 0.0026
hormone-related agents 24.0 ± 71.1 16.1 ± 39.0 -7.84 (1.26) <0.0001
Dysmenorrhea, n 7456 4246
Antianemics 7.9 ± 37.4 5.7 ± 24.1 -2.81 (0.62) < 0.0001
Hemostatics 4.8 ± 24.8 2.8 ± 11.8 -2.13 (0.40) < 0.0001
Analgesics 41.0 ± 61.8 37.2 ± 47.0 -3.46 (1.07) 0.0013
hormone-related agents 17.1 ± 56.2 12.5 ± 33.1 -4.96 (0.94) <0.0001
aMultivariate linear regression model that was adjusted for age, income, occupation, area, and iron-deficiency anemia, infertility, excessive bleeding, and dysmenorrhea.
bN, subject number in a group; and n, subject number in a subgroup.
cAntianemics, including blood derivatives and iron; hemostatics, including coagulants and hemostatics; and analgesics, including non-steroid anti-inflammatory
drugs and analgesics.
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with hypermenorrhea (-7.84 days/year/patient, P < 0.0001).
Moreover, the consumption of analgesics became sig-
nificantly different between CM users and nonusers in
fibroid patients with dysmenorrhea (-3.46 days/year/
patient, P = 0.0013).
Uterine fibroid-related medical cost between CM users
and CM nonusers
The mean total medical cost of CM users was 503.9 USD,
and that of nonusers was 6294 USD per patients. After
adjusting for age, income, occupation, area, iron-deficiency
anemia, infertility, hypermenorrhea, and dysmenor-
rhea, the total annual medical cost for treating CM
users was 0.45-fold as much as that for treating CM
nonusers (Table 4). Among the total medical cost,
although the annual cost of Chinese medicine was 16.9
USD higher for CM users than that for CM nonusers,
the annual cost of OPD (-13 USD/year, P < 0.0001),
IPD (-5611 USD/year, P < 0.0001), and ER (-2.23 USD/
year, P < 0.0001) for CM users were lower than that for
CM nonusers.Discussion
CM is used by patients with uterine fibroids as an alterna-
tive to conventional western medicine. This study com-
pared the consumption of conventional western medicine
and the exact medical cost between CM users and nonu-
sers in fibroid patients. Although more CM users were
co-morbid with iron-deficiency anemia, hypermenorrhea,
dysmenorrhea, and infertility, they consumed less fibroid-
related western medicines than CM nonusers. The differ-
ence in western medicine consumption between the two
groups enlarged in patients with co-morbidities. Moreover,
the utilization of CM did generate an extra medical cost,
however, the total NHI-reimbursed annual health care fee
per patient in CM users was substantially lower than that
in CM nonusers.
Social-demographic trends regarding CM users in this
study, which were extracted from a population-based
database from 1996 to 2010, found that CM users in fi-
broid patients were more likely to be younger and white
collar than nonusers. These trends was coincident with a
previous study that extract patients from 2000 to 2003
[13], and also with studies on female-specific diseases,
Table 4 Uterine fibroid-related cost in CM-users and nonusers
Cost, US$/patient/year Linear regression modela
Typeb CM nonusers CM users β (SE) P value
Total cost 6294 ± 41366 503.9 ± 4946 0.45 (1.05) <0.0001
OPD 16.9 ± 146.5 4.57 ± 28.8 0.75 (1.02) <0.0001
IPD 6274 ± 41317 480 ± 4833 0.26 (1.07) <0.0001
surgery 2931 ± 19328 213 ± 1980 0.27 (1.07) <0.0001
other (medication and admission) 3335 ± 25854 261.23 ± 3233 0.27 (1.07) <0.0001
ER 2.111 ± 164.2 0.097 ± 3.51 0.60 (1.44) <0.0001
CM 0.26 ± 7.37 18.7 ± 597.7 2.67 (1.17) <0.0001
aMultivariate linear regression model for nature log transformation of cost and model was adjusted for age, income, occupation, area, iron-deficiency anemia,
infertility, excessive bleeding, and dysmenorrhea.
bOPD, outpatients, IPD, inpatients, ER, emergency room, and CM, Chinese medicine.
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endometriosis [18]. In terms of co-morbidities, including
iron-deficiency anemia, hypermenorrhea, dysmenorrhea,
and infertility, this study showed that fibroid patients
with co-morbidities tended to use CM, implying severe
patients with symptoms were more likely to seek for
alternative treatments. Several studies have also reported
that most alternative medicine users are with symptoms
of chronic diseases and poor health status [19-21], and
“suffering from disease” is considered one of an important
factors that triggers patients to use CM [19].
Similar to those being associated to CM, high frequencies
of taking conventional western medicine were associated
with co-morbidities of hypermenorrhea, iron-deficiency
anemia, and dysmenorrhea were associated with. However,
patients who were co-morbid with infertility consumed less
conventional western medicine than patients who were not
co-morbid with infertility. Other social-demographic fac-
tors that associated with high consumption of conventional
western medicine included age higher than 40, being blue
collar, income less than 520 USD/month, and registration
of the insurance in Central and Southern Taiwan. In terms
of using CM, CM users were less likely to consume con-
ventional medicine, indicating that CM users reduced the
use of conventional western medicine when they chose
CM to treat diseases.
Antianemics, hemostatics, analgesics, and hormone-
related agents are commonly suggested medicines to con-
trol fibroid-related symptoms, i.e., iron-deficient anemia,
hypermenorrhea, and dysmenorrhea [4]. As medications
are only used in patients with well-defined signs or symp-
toms, among patients with a specific co-morbidity, the
difference in the consumption of a co-morbidity-specific
medicine implied that CM substituted traditional western
medicine to treat this co-morbidity for CM users. For
example, among patients co-morbid with hypermenor-
rhea, the low consumption of hemostatics in CM users
implied CM substituted hemostatics to control symptomsof hypermenorrhea. Our data implied that CM might be
useful to control symptoms caused by uterine fibroid. Ani-
mal studies and clinical studies have reported that CM
might have two beneficial effects on uterine fibroid. First,
CM is able to treat the symptoms related to uterine fi-
broid. Second, CM is able to reduce the size of fibroids.
An animal study has shown that Shao-fu-zhu-yu decoc-
tion, a commonly used CM formula for dysmenorrhea,
has been shown to relieve uterine contraction pain by its
peripheral analgesic activities [22]. Another animal study
reported that Bak-foong pills are able to directly down-
regulate mouse uterine tone [23]. However, clinical trials
regarding the efficacy of CM on uterine fibroids are not of
good quality. A systemic review reported that only two of
21 clinical trials are with strict randomization and blinding
processes. These two rigorous randomized controlled trials
reported that herbal preparation made fibroids to shrink,
but the size reduction of fibroids by herbal preparation did
not differ from the efficacy of mifepristone [24]. The
present study provided epidemiological evidence showing
difference in consumption of conventional western medi-
cine between CM users and nonusers among fibroid pa-
tients, implying therapeutic effects to release symptoms
caused by fibroids.
Complementary and alternative medicine is considered
less expensive than conventional western medicine [11,12],
and the mean cost per visit is lower for CM than for con-
ventional western medicine [9]. However, since the use of
CM generates a component of medical cost, whether using
CM decreases the total medical cost is controversial. A
review article concludes that there is still a lack of cost-
effectiveness research in CM [25]. This study found that
the use of CM did reduce total medical cost paid by na-
tion’s health-care system for uterine fibroid. Although there
was an extra expenditure in CM (18.7 USD/year/patient)
spent by CM users, this extra expenditure was much less
than the expenditure in conventional western medicine in
both of the groups. Moreover, as CM users reduced the
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from NHI for CM users was 5610 UDS/year/patient less in
CM users than in nonusers. The costs of uterine fibroids
for OPD, IPD, and ER in CM users were all lower than that
in CM nonusers. The major difference in medical cost be-
tween CM users and nonusers was the in-patient cost. CM
users saved more than 2,622 dollars in the cost of surgery
and 2,987 dollars in the cost of hospital admission and
inpatient medication per patient annually, indicating CM
users underwent less surgery and less hospitalization than
CM nonusers. The present group has reported that CM
users were more unlikely to under uterine surgery, in-
cluding hysterectomy and myomectomy, with a hazard
ratio of 0.18 [13]. This study confirmed that the decreased
surgery rate in CM users reduced health care spending in
uterine fibroid.
Using a database from the NHI, which is a government-
run, single-payer national health insurance program that
insures over 97% of citizens and over 99% of health-care
institutes [26,27], this study provided epidemiological evi-
dence showing different amount of conventional western
medicine consumption and different medical cost between
CM users and nonusers among patients with uterine fi-
broids. However, the first limitation of this study was that
we could not verify whether patients underwent other
forms of alternative medicines that are not covered by
NHI, although the proportional of patients who took
those alternative medicines was presumed small because
of their high prices. The second limitation of this retro-
spective study was that it could not directly provide
evidence for the efficacy of CM, but could only find a
correlation between using CM and low consumption of
western medicine and low cost. This correlation could also
possibly come from the difference in healthcare seeking
behavior between CM users and nonusers. Nevertheless,
whatever the underlying reason was, this study highlighted
that CM was associated with low consumption of conven-
tional western medicine and low medical cost in fibroid
patients. For practitioners, this study provided evidence
that CM might be a potential therapeutic substitute for
conventional western medicines to treat several symptoms
of uterine fibroids. Moreover, for insurance policy makers,
this study suggested that CM might be a proper area for
health insurance to cover in fibroid patients.
Conclusion
This study revealed that CM reduced the consumption
of conventional medicine, including total fibroid-related
conventional medicine and three categories of conventional
medicines (antianemics, hemostatics, and hormone-related
agents) that are commonly used to release symptoms of
fibroids. Moreover, although using CM increased a small
amount of medical cost, the total medical cost for treating
fibroid was less in CM users than in nonusers. Our resultsimplied that CM might be a potential therapeutic substitute
for conventional medicines to treat uterine fibroids with
low cost.
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